GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (STU:RB0) » Definitions » Inventories, Finished Goods

Regenxbio (STU:RB0) Inventories, Finished Goods : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Regenxbio Inventories, Finished Goods?


Regenxbio Inventories, Finished Goods Historical Data

The historical data trend for Regenxbio's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenxbio Inventories, Finished Goods Chart

Regenxbio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regenxbio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Regenxbio Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Regenxbio Business Description

Industry
Traded in Other Exchanges
Address
9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Regenxbio Headlines

No Headlines